



## PHARMACEUTICAL 2017











## PHARMACEUTICAL 2017



## Syros Pharmaceuticals Inc. Rank 72 of 292



The relative strengths and weaknesses of Syros Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syros Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 103% points. The greatest weakness of Syros Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 184%, being 181% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	85,508
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,567
Liabilities, Non-Current	0
Other Assets	965
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	537
Other Revenues	0
Property and Equipment	4,850
Research and Development	37,817
Selling, General and Administrative Expense	10,463

Output Variable	Value in 1000 USD
Assets	91,323
Liabilities	9,567
Expenses	48,280
Revenues	0
Stockholders Equity	81,756
Net Income	-47,743
Comprehensive Net Income	-47,743
Economic Capital Ratio	184%

